Navigation Links
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
Date:12/10/2010

s of Health Registry indicate that without treatment, patients in the United States with PAH have a median survival time of approximately three years from diagnosis.

About APD811APD811, a potent and selective agonist (or activator) of the prostacyclin receptor, is Arena's internally discovered drug candidate for the treatment of PAH. Prostacyclin receptor agonists, through regulation of vascular smooth muscle tone, improve mortality and exercise tolerance in PAH patients and are among the treatments administered as standard of care for advanced PAH. Currently available prostacyclin receptor agonists belong to the prostanoid class of molecules and these products need to be administered frequently or continuously through intravenous, subcutaneous or inhaled routes. Arena believes that APD811, as a non-prostanoid prostacyclin agonist, has the potential to improve the standard of care for PAH by providing an oral form of administration with clinical benefits similar to currently available prostacyclin receptor agonists.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States following FDA approval of the New Drug Application for lorcaserin.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include s
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
2. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
3. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
4. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
5. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
6. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
7. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
8. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
9. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
11. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... MENLO PARK, Calif. , Oct. 27, 2014 /PRNewswire/ ... isolation of blood flow and delivery of fluids to ... the RenovoRx Board of Directors has appointed Shaun ... additional Member of the RenovoRx Board of Directors. Bagai ... medical technology industry. Bagai joined RenovoRx in ...
(Date:10/27/2014)... Research and Markets has announced the ... report to their offering. H1N1 influenza (zoonotic) ... of the swine H1N1 virus, known as H1N1v virus. The ... and lungs. H1N1 virus is an RNA virus belonging to ... such as humans, swine, birds, seals, and horses. Influenza A ...
(Date:10/27/2014)... CHICAGO , Oct. 27, 2014  Demonstrations ... and devices are being featured this week in ... 2014 Scientific Assembly where more than 7,000 emergency ... medicine and participating in educational courses. ... back drop of true-to-life emergency department environments, including ...
Breaking Medicine Technology:RenovoRx Board Names Shaun R. Bagai as CEO 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
... study presented at the American Association of Physicists in Medicine ... showed that 18FDG dose for Positron Emission Mammography (PEM) may ... quality. PEM scanners are high-resolution breast PET systems ... of a lesion.  The metabolic view assists physicians to make ...
... Aug. 23 Encorium Group, Inc. (Nasdaq: ENCO ... studies in over 30 countries for many of the world,s ... to commence a rights offering for up to 3,401,151 shares ... offering, each stockholder of record as of August 11, 2010 ...
Cached Medicine Technology:Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging 2Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging 3Encorium Group, Inc. Announces Terms of Proposed Rights Offering 2Encorium Group, Inc. Announces Terms of Proposed Rights Offering 3Encorium Group, Inc. Announces Terms of Proposed Rights Offering 4
(Date:10/30/2014)... PreDiabetes Centers , the pioneer ... shoppers with a supply of sugardown®, a chewable dietary ... blood sugar spikes. Learning how to control blood sugar ... of a diabetes prevention plan. , Shoppers who spend ... tube of sugardown. The offer expires November 30. ...
(Date:10/30/2014)... October 30, 2014 Radio listeners who ... questions about the impact of traditional radio commercials and ... most likely to influence a purchasing decision. , Those ... 525 consumers conducted by radio marketing company CRN International. ... isolating the results of respondents who indicated they have ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... been identified that appear linked to autism spectrum disorders, ... are on their way to discovering up to 1,000 ... Autism spectrum disorders include a range of developmental disabilities ... An estimated one in 68 U.S. children has an ...
(Date:10/30/2014)... October 30, 2014 Home Care Assistance ... provider of non-medical, in-home senior care, is weighing in ... brain health. , The study, performed by the University ... 60 and 78 over a week-long period and observed ... daily physical activity. By examining the structural soundness of ...
(Date:10/30/2014)... 2014 Horse Sense & Sensitivity ... to special needs individuals in the Jacksonville area, will ... 15 from 10-2:00 p.m. at Bailey's Farm (2202 Bishop ... the public and is designed to raise awareness and ... the HSS Round-Up is free. Ticket purchases will be ...
Breaking Medicine News(10 mins):Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2
... of Notre Dame researcher, is one of the coauthors of a ... academia and industry that calls for strong steps to be taken ... group issued a priority list of steps that need to be ... paper is an outgrowth of a meeting the group held at ...
... help personalize pain medication management for sickle cell disease ... Dr. Cheedy Jaja, a nurse research scientist and Assistant ... Institutes of Health grant to determine if variations in ... could help physicians manage sickle cell pain. ...
... CT and MRI scansis important to cancer screening, treatment, ... emerging, and with it, the need for imaging specialists ... Institute (HCI) at the University of Utah has demonstrated ... National Cancer Institute (NCI) naming HCI a Center for ...
... is available in French . , Researchers ... control of the integrity of our genetic code, and when ... important role in the development of cancer. The University of ... their discovery by using cutting edge microscopy techniques to visualize ...
... -- Some women who inherit the BRCA1 or BRCA2 breast ... with breast cancer nearly a decade earlier than those who ... Researchers examined the family trees of 128 breast or ... determine the origins of the patients, cancer genes. "No ...
... American songbirds completed by the Department of Biology at ... has discovered these birds differ dramatically in colour and ... they are on the road to becoming a new ... species could change, that they were not the unaltered, ...
Cached Medicine News:Health News:New paper calls for strong steps to tackle antibiotic resistance 2Health News:Study probes genetic link to sickle cell pain management 2Health News:Study probes genetic link to sickle cell pain management 3Health News:Study probes genetic link to sickle cell pain management 4Health News:Huntsman Cancer Institute awarded top honors as cancer imaging facility 2Health News:Scientists capture single cancer molecules at work 2Health News:Family Tree May Affect Diagnosis Age in Some Breast Cancers 2
... patented HEp-2 cell line that has been ... SS-A/Ro autoantibodies, without affecting the other ANA ... published worldwide on the HEp-2000 ANA substrate, ... when used in place of standard HEp-2 ...
... ANA and ENA assays can be ... for antinuclear antibodies, which are associated ... as Systemic lupus erythematosus (Lupus), Sjgren's ... systemic sclerosis, scleroderma, polymyositis, dermatomyositis, and ...
... ANA and ENA assays can be ... for antinuclear antibodies, which are associated ... as Systemic lupus erythematosus (Lupus), Sjgren's ... systemic sclerosis, scleroderma, polymyositis, dermatomyositis, and ...
... and ENA assays can be used ... antinuclear antibodies, which are associated with ... Systemic lupus erythematosus (Lupus), Sjgren's syndrome, ... sclerosis, scleroderma, polymyositis, dermatomyositis, and Raynaud's ...
Medicine Products: